Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide analysis of mRNA expression profile in MDA-MB-231 cells treated with or without 3.75 μM DCC-2036 for 48 hours.

ABSTRACT: Our study found that DCC-2036, the novel tyrosine kinase inhibitor, has potent activity against triple negative breast cancer (TNBC). To better understand the molecular mechanisms involving in the effect of DCC-2036 on TNBC cells, the whole genome-wide transcriptome profile of MDA-MB-231 cells (a representative TNBC cell line) cultured with or without DCC-2036 was analyzed by cDNA microarray.

ORGANISM(S): Homo sapiens

PROVIDER: GSE109230 | GEO | 2021/01/14

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Genome-wide analysis of mRNA expression profile in MDA-MB-231 cells treated with or without 3.75 μM DCC-2036 for 48 hours.

Project description:Genome-wide analysis of mRNA expression profile in MDA-MB-231 cells treated with or without 3.75 μM DCC-2036 for 48 hours.

| PRJNA430226 | ENA

Expression data from parental MDA-MB-231 cells and MDA-MB-231(SA) variant

Project description: Not available

| S-ECPF-GEOD-20085 | biostudies-other

RNA-seq of MDA-MB-231 siCt and siAXL

Project description:Triple-Negative breast cancer (TNBC) is an aggressive subtype of breast cancer that is associated with poor prognosis due to its propensity to form metastases. Unfortunately, the current treatment options are limited to chemotherapy such that identification of actionable targets are needed. The receptor tyrosine kinase AXL plays a role in the tumor cell dissemination and its expression in TNBC correlates with poor patients? survival. Here, we explored whether exploiting an AXL knockdown gene signature in TNBC cells may offer an opportunity for drug repurposing. To this end, we queried the PharmacoGx pharmacogenomics platform with an AXL gene signature which revealed Phenothiazines, a class of Dopamine Receptors antagonists (Thioridazine, Fluphenazine and Trifluoperazine) typically used as anti-psychotics. We next tested if drugs may be active to limit growth and metastatic progression of TNBC cells, similarly to AXL depletion. We found that the Phenothiazines were able to reduce cel l invasion, proliferation and viability, and also increased apoptosis of TNBC cells in vitro. Mechanistically, these drugs did not affect AXL activity but instead reduced PI3K/AKT/mTOR and ERK signaling. When administered to mice bearing TNBC xenografts, these drugs showed were able to reduce tumor growth and metastatic burden. Collectively, these results suggest that these antipsychotics are novel anti-tumor and anti-metastatic agents that could potentially be repurposed, in combination with standard chemotherapy, for use in TNBC.

2019-04-01 | GSE120268 | GEO

sc-lineage TNBC MDA-MB-231

Project description:Single-cell transcriptional lineage tracing TNBC MDA-MB-231

| PRJEB53139 | ENA

Effects of FSTL1 on cell proliferation in breast cancer cell line MDA‑MB‑231 and its brain metastatic variant MDA‑MB‑231‑BR.

Project description: Not available

| S-EPMC5780039 | biostudies-literature

Citral induced apoptosis in MDA-MB-231 spheroid cells.

Project description: Not available

| S-EPMC5809808 | biostudies-literature

Hypoxic MDA-MB-231 miRNA array

Project description: Not available

| S-ECPF-GEOD-64436 | biostudies-other

RNA-seq analysis CARM1 knockdown effect on MDA-MB-231 cells

Project description:Coactivator associated arginine methyltransferase 1 has been reported to play paramount roles in estrogen receptor alpha (ERα)-positive breast cancer. It promotes breast cancer development and metastasis. However, little research about CARM1 has been focused on triple-negative breast cancer (TNBC). Here, we report that CARM1 promotes proliferation, epithelial-mesenchymal transition (EMT) and stemness in TNBC. CARM1 transactivates Hypoxia-inducible factor 1 subunit alpha (HIF1A) and is physically associated with it. They function together in a concerted complex to regulate downstream targets and promote the carcinogenesis and metastasis of TNBC.

2024-02-24 | GSE167394 | GEO

Influence of LRP-1 on MDA-MB-231 secretome

Project description:LRP-1 (low-density lipoprotein receptor-related protein-1) receptor is a multifunctional endocytosis receptor that is part of the LDL receptor family. Due to its capacity to control the pericellular level of various growth factors and proteases, LRP-1 plays a crucial role in controlling the dynamics of the membrane proteome. LRP-1 overexpression in breast cancer, prompted us to take an interest in its involvement in tumor progression. An RNA interference strategy in MDA-MB-231 line was used, based on shRNA stable expression. In addition to integrated experimental strategies (in vitro and in vivo) through combined approaches of biochemistry, molecular biology, cell biology, multimodal preclinical imaging, proteomics allowed us to compare shLRP-1 MDA-MB-231 tumor conditioned media to shCtrl MDA-MB-231 tumor conditioned media in order to identify secreted molecular targets modulate by LRP-1 repression and thus provide a better understanding of its regulatory action within the TNBC microenvironment.

2022-02-16 | PXD022978 | Pride

Elastin molecular aging promotes MDA-MB-231 breast cancer cell invasiveness.

Project description: Not available

| S-EPMC6120250 | biostudies-literature